How Many Clicks Is 0.25 mg on a 1 mg Ozempic Pen? Off-Pen Math

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · Author: FormBlends Editorial

Key Takeaways

• The 1 mg Ozempic pen will dial to 0.25 mg at four clicks because the cartridge shares concentration with the starter pen.
• The labeled format for the 0.25 mg starting dose is the 0.25/0.5 mg starter pen, not the 1 mg pen.
• Patients ask about this conversion mainly during shortages or unplanned step-downs from a higher dose.
• The 1 mg pen mechanically supports the 0.25 mg position, but Novo Nordisk has not validated this use.
• Off-label use of one pen to deliver a different pen's labeled dose should be discussed with the prescriber, not improvised.

Direct answer

Four clicks on a 1 mg Ozempic pen brings the dose counter to approximately 0.25 mg. The 1 mg pen and the 0.25/0.5 mg starter pen use the same cartridge concentration (1.34 mg/mL), so the per-click value (~0.0625 mg) is identical. The labeled use of the 1 mg pen is four 1 mg doses, not sixteen 0.25 mg doses. The starter pen is the FDA-approved format for the 0.25 mg dose.

Table of contents

1. The four-click answer and what it means
2. Why the math works: shared concentration
3. The labeled-use gap
4. Three reasons patients ask this question
5. Shortage workarounds: a brief history
6. What prescribers do when they want a patient on 0.25 mg without a starter pen
7. Risks of self-directed micro-dosing
8. The mechanical safety of the dial at low positions
9. The contrary view: do we really need the starter pen?
10. Decision framework
11. FAQ
12. Sources

The four-click answer and what it means

On the Ozempic 1 mg pen, the dose counter advances from 0 to 1 mg in 16 clicks. Each click is approximately 0.0625 mg. Four clicks lands on 0.25 mg, eight clicks on 0.5 mg, and sixteen on 1 mg. The dose window will display 0.25 mg when the dial has reached that position, the same as on the starter pen.

The math is identical because the chemistry is identical. The 1 mg pen and the starter pen both deliver semaglutide at 1.34 mg/mL. The differences between the two pens are cartridge volume (3 mL on the 1 mg pen, 1.5 mL on the starter pen) and the dose stops the manufacturer chose to label.

Why the math works: shared concentration

Novo Nordisk designed the 0.25/0.5 mg starter pen and the 1 mg maintenance pen around the same concentration so that escalation across the two formats would be predictable. The dose dial geometry is the same. The dose window numbers shift, but the underlying mechanism is shared.

Pen	Cartridge contents	Concentration	Per-click value	Labeled doses
0.25/0.5 mg starter pen	2 mg in 1.5 mL	1.34 mg/mL	0.0625 mg	0.25 mg, 0.5 mg
1 mg maintenance pen	4 mg in 3 mL	1.34 mg/mL	0.0625 mg	1 mg
2 mg high-dose pen	8 mg in 3 mL	2.68 mg/mL	0.125 mg	2 mg

This is why dialing 0.25 mg on a 1 mg pen produces the same delivered milligrams as dialing 0.25 mg on the starter pen. Four clicks, 0.25 mg of semaglutide.

The labeled-use gap

Novo Nordisk's prescribing information lists the labeled use for each pen. The 1 mg pen is labeled "for the maintenance dose of 1 mg once weekly." It is not labeled for 0.25 mg or 0.5 mg, even though the dial passes those positions on the way to 1 mg.

This matters for three reasons.

First, the FDA-approved indication, dose, and device format are linked. A patient using a 1 mg pen to deliver 0.25 mg is outside the labeled use of the device, even though the molecule and concentration are correct.

Second, the pen's overfill (the small extra volume beyond labeled doses) is calibrated for the labeled use. A 1 mg pen used to deliver sixteen 0.25 mg doses may run out earlier than the math suggests because the overfill is designed for four uses, not sixteen.

Third, the storage-after-first-use rules (56 days at room temperature or refrigerated) were validated for the labeled use. Stretching a pen across more weeks than the label intended pushes the medication past validated stability data.

Three reasons patients ask this question

This is a niche question with predictable triggers.

Reason 1: shortage. From 2022 through 2024, the FDA listed semaglutide on its drug shortages database. Patients who could fill a 1 mg pen but not a starter pen sometimes wanted to use the 1 mg pen for the introductory weeks of therapy.

Reason 2: step-down. A patient on 1 mg who develops intolerable side effects may need to drop back to 0.25 mg or 0.5 mg temporarily. Rather than waiting for a new starter pen, some prescribers tell patients to use the partial volume in their current 1 mg pen at the lower dose for one or two weeks.

Reason 3: confusion. A patient who has just switched from a starter pen to a 1 mg pen may want to confirm the click math is the same. It is, but the labeled use is not.

Shortage workarounds: a brief history

During the 2022-2024 semaglutide shortage, online forums and patient communities developed several workarounds. The most common involved using a 1 mg pen for early titration when no starter pen was available. The math worked. The label did not.

The FDA explicitly warned in May 2023 about compounded and altered dosing schedules that diverged from approved protocols. The agency cited reports of incorrect doses, severe nausea, and hospitalization. The warnings applied primarily to compounded semaglutide, but the concerns extended to branded pens used outside their labeled instructions.

By mid-2026, supply has stabilized. The shortage rationale for using a 1 mg pen at sub-labeled doses no longer applies in most cases. Patients should expect to be able to fill the correct pen for their dose.

What prescribers do when they want a patient on 0.25 mg without a starter pen

When a clinical situation requires a patient to take 0.25 mg without a starter pen, prescribers have several options.

Option 1: write for a new starter pen. This is the labeled path. Most insurance plans will cover this, especially with a clear indication.

Option 2: write a documented off-label instruction. The prescriber writes that the patient should use the 1 mg pen and dial to the 0.25 mg position. This documents the clinical decision in the medical record.

Option 3: switch to compounded semaglutide. Compounded preparations from 503A pharmacies are not FDA-approved but are easier to titrate in custom volumes. A 0.25 mg dose from a 2.5 mg/mL vial is 0.10 mL on a U-100 syringe.

Option 4: pause therapy temporarily. If side effects from 1 mg are severe enough to require a step-down, sometimes the appropriate response is a one- or two-week pause followed by a restart on the correct pen.

Risks of self-directed micro-dosing

The risks of using a 1 mg pen to deliver 0.25 mg without prescriber direction are concrete.

Risk 1: dose error. Counting clicks instead of reading the dose window is more error-prone, especially at the smaller dial positions. A patient who delivers 0.3 mg instead of 0.25 mg by accident may trigger more nausea than expected.

Risk 2: stability concerns. Stretching a pen across more weeks than the label validates introduces uncertainty about drug stability, especially in the closing weeks of an over-extended pen's life.

Risk 3: insurance and refill problems. Insurance plans expect a 1 mg pen to last four weeks. A patient who reports stretching the pen across more weeks may trigger refill timing problems on the next prescription.

Risk 4: medical-legal documentation. If an adverse event occurs while a patient is using a pen outside its labeled instructions, the response from the clinic and pharmacy may be slower or more complicated.

The mechanical safety of the dial at low positions

One frequently asked question: is the 1 mg pen's dial safe at the lower positions? Mechanically, yes. The dial is designed to land on any position between 0 and 1 mg, and Novo Nordisk's instructions for use explicitly note that the dial can be turned forward and backward without losing medication.

The integrity of the dose at low positions depends on three things: the dial actually reaches the labeled position, the pen has not been damaged or dropped, and the medication has been stored within label conditions. If those three are true, the delivered dose at the 0.25 mg position on a 1 mg pen is the same 0.25 mg that would come from a starter pen.

The contrary view: do we really need the starter pen?

A small number of clinicians have argued that the 0.25/0.5 mg starter pen is more of a regulatory artifact than a clinical necessity. Their case rests on several points.

Point 1: the molecule and concentration are the same as the 1 mg pen. There is no chemical reason for two devices.

Point 2: a 1 mg pen could theoretically handle the entire titration plus the first month of maintenance, if a patient used it across more than four weeks at low doses.

Point 3: pharmacy and insurance friction at the starter-to-maintenance transition adds steps and gaps in therapy that could be avoided with a single pen format.

Counter-arguments: the starter pen exists to make the 0.25 mg and 0.5 mg doses easy to deliver correctly, with dose stops designed for those specific values; insurance and supply chains have built around the existing format; consolidating to one pen would not necessarily reduce cost. Novo Nordisk maintains the two-pen system, and prescribers generally accept it.

Decision framework

If you have a starter pen available:

• Use it. The starter pen is the FDA-approved format for 0.25 mg.
• Do not dial 0.25 mg on a 1 mg pen just because the math works.

If your prescriber has specifically directed you to use a 1 mg pen at 0.25 mg:

• Confirm the instruction in writing.
• Read the dose window, not just the click count. Four clicks lands on 0.25 mg if the dial is engaging cleanly.
• Track the date you opened the pen; the 56-day room-temperature limit still applies.

If you are considering this on your own to save money or stretch supply:

• Do not. Talk to your prescriber first.
• If cost is the issue, ask about compounded semaglutide options or manufacturer savings programs.

What this means for your dose schedule

Follow your prescriber's instructions, and do not adjust dose without their approval.

FAQ

How many clicks is 0.25 mg on a 1 mg Ozempic pen?

Four clicks. The 1 mg pen uses the same cartridge concentration as the starter pen, so the per-click value (~0.0625 mg) is identical. The labeled use of the 1 mg pen, however, is four 1 mg doses.

Why are people dialing 0.25 mg on a 1 mg pen?

Shortage workarounds, step-downs from a higher dose, or confusion about whether the click math transfers between pens.

Does the 1 mg pen actually show 0.25 mg in the dose window?

Yes. The dial passes through the 0.25 mg position on the way to 1 mg, and the window displays the value when the dial stops there.

Is it safe to use the 1 mg pen to deliver 0.25 mg?

Mechanically, yes. Clinically, only if your prescriber has directed this and documented it. Novo Nordisk has not labeled the 1 mg pen for the 0.25 mg dose.

How many 0.25 mg doses could you get from a 1 mg pen?

Mathematically sixteen, since 4 mg divided by 0.25 mg equals 16. The labeled use is four 1 mg doses.

Do prescribers ever direct patients to use a 1 mg pen this way?

Some do, especially during shortages or for step-downs. The decision should be documented and the patient should not improvise.

Is the 0.25 mg click count the same on the 2 mg pen?

No. The 2 mg pen uses a different concentration (twice as concentrated), so the per-click value is doubled. Two clicks on the 2 mg pen approximates 0.25 mg, but the dose window on that pen is not engineered for that position.

Does the dose counter stop at 0.25 mg on a 1 mg pen?

Not as a hard stop. The 1 mg pen will dial through the 0.25 and 0.5 positions on its way to 1 mg. The patient must stop the dial manually at the desired position.

Will insurance cover both pens at the same time?

Usually no. Insurance plans typically expect one pen per script. Asking for a starter pen and a 1 mg pen simultaneously may trigger a denial.

What if my 1 mg pen seems to be running out faster than expected?

If you are using it for the labeled four 1 mg doses, contact the pharmacy. If you are stretching it for sub-labeled doses, the overfill calibration may not cover the additional uses.

Related guides

• How Many Clicks Are in a 1 mg Ozempic Pen? The Math Behind the Counter
• How Many Clicks on a 2 mg Ozempic Pen? The High-Dose Click Math
• How Many Clicks for 0.25 mg Ozempic? The First-Dose Math
• How Many Clicks for 0.5 mg Ozempic? The Second-Step Math
• Counting Clicks in the Ozempic 2 mg Pen: The Dose-Math Patients Actually Want
• How Many Doses in an Ozempic Pen? The Full Capacity Breakdown
• Tool: dosage calculator

Sources

1. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. Revised 2024.
2. Novo Nordisk. Ozempic Instructions for Use, 1 mg pen. 2023.
3. Novo Nordisk. Ozempic Instructions for Use, 0.25/0.5 mg pen. 2023.
4. FDA. Semaglutide drug shortage timeline. FDA Drug Shortages Database, accessed 2026.
5. FDA. Compounded versions of GLP-1 medicines: safety considerations. May 2023 statement.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
7. ISMP. Medication Safety Alert: Errors with Ozempic and Wegovy Pens. 2023.
8. ADA. Standards of Care in Diabetes 2026.
9. Endocrine Society. Clinical Practice Guideline on Pharmacologic Management of Obesity. 2015 (updated 2024).
10. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy (SUSTAIN 1). The Lancet Diabetes & Endocrinology. 2017.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients to licensed prescribers and U.S. pharmacies. We do not authorize, instruct, or facilitate off-label use of any pen format. All clinical decisions belong to the prescriber.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved and is not equivalent to Novo Nordisk's Ozempic pen. Compounded preparations from 503A pharmacies are prepared for individual prescriptions.

Results Disclaimer. Pen mechanics determine delivered milligrams; therapeutic outcome depends on prescriber-directed dose, adherence, and individual response. Dialing a sub-labeled dose on a 1 mg pen does not guarantee the same clinical experience as using the starter pen.

Trademark Notice. Ozempic is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with or endorsed by Novo Nordisk.